Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04231864
Title Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alain Algazi
Age Groups: senior | adult
Covered Countries

No variant requirements are available.